Table 1

Key model parameters
Parameter Value References
Baseline Fracture Risks based on Fx type, age, and gender, BMD [2,13]
Fracture Relative Risks - GIOP by fracture type based on age [13]
Fracture after Fracture and Second Fracture Relative Risks based on fracture type and age [13,14]
Drug Costs Teriparatide- Avg. Daily Cost: €14.74 [15]
Alendronate – Avg. Daily Cost: €0.42
Acute and Long-Term Direct Fracture Costs by age and fracture type [14,28]
Currency SEK to € Conversion 9.0335 ; 12 month average ending December 2011 [16]
Continuing 6 Month Care Costs €201 (months 1–6,13-18) [17]
€194 (months 7–12)
Natural Mortality Swedish Life Tables based on age and gender; adjusted to remove osteoporosis fracture deaths [13,18]
Fracture Mortality based on age and gender; [13]
0.007 (65 year male) to 0.0375 (90+ year old female)
Relative Risk of Mortality Post Fracture For hip fractures and vertebral fractures; ranges: 2.5 (year 1) to 1.0 (year 7) [19,20]
Base Health Utilities by age; from 0.84 (through age 50) to 0.65 (age 85) [21]
Fracture Utility Multipliers first year and subsequent years, by fracture type [13]
Teriparatide Anti-Fracture Efficacies Relative Risks by fracture type and treatment period [4-7]
Bisphosphonate Anti-Fracture Efficacies Relative Risks by fracture type and treatment period [13]
Teriparatide Discontinuation 3, 9, and 15 month values interpolated to 6 month cycles [22]
Bisphosphonate Discontinuation by 6 month cycle [23]

Murphy et al.

Murphy et al. BMC Musculoskeletal Disorders 2012 13:213   doi:10.1186/1471-2474-13-213

Open Data